Vicore Pharma Holding AB Sponsored ADR AI Stock Analysis
Vicore Pharma Holding AB Sponsored ADR (VCRE) AI Stock Analysis
Vicore Pharma Holding AB Sponsored ADR
(NASDAQ:VCRE)
No summary available
Vicore Pharma Holding AB Sponsored ADR (VCRE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $279.65M
- Dividend Yield
- ―
- Average Volume (3M)
- 23.28K
- Price to Earnings (P/E)
- -5.5
- Beta (1Y)
- 0.55
- Revenue Growth
- -50.05%
- EPS Growth
- -9.20%
- Country
- US
- Employees
- 37
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Vicore Pharma Holding AB Sponsored ADR Business Overview & Revenue Model
Company Description
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clin...
Vicore Pharma Holding AB Sponsored ADR Peers Comparison
Overall Rating
QTTB55Neutral
KROS51.05Neutral
UPB43Neutral
CRBP40Underperform
GALT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | $258.24M | 2.73 | 26.77% | ― | ― | ― | |
| 51Neutral | $235.49M | -4.27 | -21.85% | ― | -83.48% | -277.31% | |
| 43Neutral | $114.01M | -0.69 | -57.09% | ― | 2.54% | -31.89% | |
| 40Underperform | $62.03M | -0.43 | -100.96% | ― | ― | -10.49% | |
| 40Underperform | $293.55M | -8.84 | 21.65% | ― | ― | 42.26% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VCRE | Vicore Pharma Holding AB Sponsored ADR | 9.90 | -3.56 | -26.47% | |
| GALT | Galectin Therapeutics (GALT) | 2.98 | -2.76 | -48.08% | |
| CRBP | Corbus Pharmaceuticals Holdings | 2.75 | -8.95 | -76.52% | |
| QTTB | Q32 Bio Inc | 8.53 | 6.60 | 341.97% | |
| KROS | Keros Therapeutics, Inc. | 12.00 | -4.82 | -28.66% | |
| UPB | Upstream Bio, Inc. | 2.08 | -22.88 | -91.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
